PBS restrictions for ezetimibe and its fixed dose combinations
Page last updated: 1 November 2024
On 1 November 2024, the PBS restriction level for ezetimibe and ezetimibe + HMG-CoA reductase inhibitor (statin) fixed dose combinations (FDCs) changed from Authority Required (STREAMLINED) to Unrestricted Benefit listings for 30-day prescriptions, and to Restricted Benefit listings for 60-day prescriptions for patients whose condition is stable. Ezetimibe is available in FDCs with atorvastatin, simvastatin and rosuvastatin.
These changes were made following consideration by the Pharmaceutical Benefits Advisory Committee (PBAC) in May 2024. Further information can be found in the May 2024 PBAC Outcomes and the full Public Summary Document is provided here:
